Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.41 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515282 | 0.91 | CYP3A4 (0.46) | KDM1AKDM1BCYP3A4TSHRMAPK1 | |
| SCHEMBL203096 | 0.83 | KDM1A (0.52) | KDM1AKDM1BCYP3A4TSHRMAPK1 | |
| SCHEMBL832391 | 0.82 | CYP3A4 (0.60) | CYP3A4TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL2536617 | 0.79 | ALDH1A1 (0.41) | KDM1AKDM1BALDH1A1POLBL3MBTL1 | |
| SCHEMBL405476 | 0.79 | CD44 (0.48) | CYP3A4TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL8121628 | 0.79 | CYP3A4 (0.55) | CYP3A4TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL4508097 | 0.79 | TSHR (0.63) | CYP3A4TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL23885388 | 0.77 | ALDH1A1 (0.40) | KDM1AKDM1BALDH1A1POLBL3MBTL1 | |
| SCHEMBL350192 | 0.77 | ALDH1A1 (0.40) | KDM1AKDM1BALDH1A1POLBL3MBTL1 | |
| SCHEMBL30053965 | 0.77 | ALDH1A1 (0.40) | KDM1AKDM1BALDH1A1POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4596551-A1 | COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY | Trasveda Ltd. (KY) | 2025-08-06 | — | — | EP | disclosed |
| WO-2024067714-A1 | COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY | 泰励生物科技（上海）有限公司 | 2024-04-04 | — | — | WO | disclosed |
| CN-117800975-A | Compounds with anti-KRAS mutant tumor activity | 泰励生物科技（上海）有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-05-25 | — | — | US | disclosed |
| EP-4125914-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| CN-115427044-A | Pyrrolopyrimidines as complement inhibitors | 拜奥克里斯特制药公司 | 2022-12-02 | — | — | CN | disclosed |
| WO-2021202977-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| WO-2018081276-A1 | COMPOUNDS | TESARO, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20100322901-A1 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION | 2010-12-23 | — | — | US | disclosed |
| US-20100322901-A1 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF | SCHERING CORPORATION | 2010-12-23 | — | — | US | disclosed |
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | SCHERING CORPORATION | 2010-04-22 | — | — | US | disclosed |
| EP-0945435-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMA CO LTD (JP) | 2003-08-13 | — | — | EP | disclosed |
| US-6136823-A | BACTERICIDES OR VIRICIDES | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| EP-0945435-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100196319-A1 | 4, 5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | KDM1A 1066/4885KDM1B 1871/4885CYP3A4 11/4885 |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | KDM1A 497/4885KDM1B 258/4885CYP3A4 666/4885 |
| US-20230159536-A1 | PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS | C5, C9, C1QBP | KDM1A 3928/4885KDM1B 4333/4885CYP3A4 1364/4885 |
| US-20100098661-A1 | 4,5-RING ANNULATED INDOLE DERIVATIVES FOR TREATING OR PREVENTING OF HCV AND RELATED VIRAL INFECTIONS | ZC3HAV1, IDO1, ZC3HAV1L | KDM1A 1161/4885KDM1B 2031/4885CYP3A4 11/4885 |
| US-20100322901-A1 | 5, 6-RING ANNULATED INDOLE DERIVATIVES AND USE THEREOF | IDO1, IDO2, TPH1 | KDM1A 681/4885KDM1B 843/4885CYP3A4 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.